From: Recent progress in mass spectrometry-based urinary proteomics
Condition | Salient features | Technology used | References |
---|---|---|---|
Normal human urinary proteomics | Studies involved cataloging, quantifying and profiling proteins in normal human urine as well as urine protein changes associated with, pregnancy, normal renal function, tobacco smoking and individual variation | LC–MS/MS HPLC-Chip-MS/MS | [10] [166] [170] [171] [172] [173] [174] [175] [176] [177] [178] [57] [16] [179] [180] [142] [47] [181] [182] [183] [184] [185] |
Urine proteomics in cancer | Application of urinary proteomics in identification of non-invasive diagnostic biomarkers for numerous cancer types including bladder cancer, prostate cancer, lung cancer, gastric cancer and cholangiocarcinoma | MALD-TOF LC–MS/MS CE-MS | [70] [186] [75] [76] [187] [72] [188] [73] [189] [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [74] [201] [151] [202] [203] [204] [205] [206] [207] [208] [209] [66] [210] [211] [212] [213] [214] [215] [216] [217] [218] [219] [220] [221] [222] [223] [224] [62] [225] [226] |
Urine proteomics in other pathologies | Pathological conditions such as urinary tract infections, diabetic nephropathy, chronic kidney disease, coronory artery disease, pre-eclampsia, tuberculosis, SARS-CoV-2 and other immunological morbidities have been assessed with the help of urine proteomics | SELDI-TOF CE-MS LC–MS/MS Targeted mass spectrometry | [227] [228] [229] [230] [231] [232] [233] [234] [235] [236] [237] [101] [85] [238] [239] [240] [241] [242] [243] [244] [245] [246] [247] [248] [249] [250] [251] [252] [253] [254] [255] [99] [256] [257] [258] [259] [260] [105] [261] [262] [263] [31] [264] [265] [266] [267] [268] [269] [90] [6] [270] [271] [91] [272] [273] [274] [56] [275] [276] [277] [278] [87] [279] [280] [281] [282] [283] [284] |